A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

Completed

Phase 2 Results

Summary of Purpose

The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of platelets. Blood clots prevent us from bleeding, but when they form inside the arteries their formation is linked to a risk of medical problems such as heart attack and stroke. This study...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 12 January 2012.

1 Oct 2007 10 Sep 2007 1 Mar 2009 1 Mar 2009 1 Jan 2012 27 Jan 2011
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions See All

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Pharmacodynamics Study
  • Intervention: Parallel Assignment

Contacts

  • AstraZeneca Clinical Study, Information 1-800-236-9933

    information.center@astrazeneca.com